132 related articles for article (PubMed ID: 35085004)
1. Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma.
Verly IRN; Matser YAH; Leen R; Meinsma R; Fiocco M; Koster J; Volckmann R; Savci-Heijink D; Cangemi G; Barco S; Valentijn LJ; Tytgat GAM; van Kuilenburg ABP
JCO Precis Oncol; 2022 Jan; 6():e2000447. PubMed ID: 35085004
[TBL] [Abstract][Full Text] [Related]
2. 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients.
Verly IRN; van Kuilenburg ABP; Abeling NGGM; Goorden SMI; Fiocco M; Vaz FM; van Noesel MM; Zwaan CM; Kaspers GJL; Merks JHM; Caron HN; Tytgat GAM
Eur J Cancer; 2018 Feb; 90():102-110. PubMed ID: 29274926
[TBL] [Abstract][Full Text] [Related]
3. Clinical validation of urine 3-methoxytyramine as a biomarker of neuroblastoma and comparison with other catecholamine-related biomarkers.
Lam L; Woollard GA; Teague L; Davidson JS
Ann Clin Biochem; 2017 Mar; 54(2):264-272. PubMed ID: 27235704
[TBL] [Abstract][Full Text] [Related]
4. Predicting amplification of
Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
[TBL] [Abstract][Full Text] [Related]
5. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
6. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.
Jung M; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DD; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ
Cancer Res; 2017 Feb; 77(4):971-981. PubMed ID: 27923830
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites.
van Duinen N; Corssmit EP; de Jong WH; Brookman D; Kema IP; Romijn JA
Eur J Endocrinol; 2013 Sep; 169(3):377-82. PubMed ID: 23832865
[TBL] [Abstract][Full Text] [Related]
8. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
9. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
[TBL] [Abstract][Full Text] [Related]
10. Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients.
Verly IR; van Kuilenburg AB; Abeling NG; Goorden SM; Fiocco M; Vaz FM; van Noesel MM; Zwaan CM; Kaspers GL; Merks JH; Caron HN; Tytgat GA
Eur J Cancer; 2017 Feb; 72():235-243. PubMed ID: 28061374
[TBL] [Abstract][Full Text] [Related]
11. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
[TBL] [Abstract][Full Text] [Related]
12. Biochemical testing for neuroblastoma using plasma free 3-O-methyldopa, 3-methoxytyramine, and normetanephrine.
Peitzsch M; Butch ER; Lovorn E; Mangelis A; Furman WL; Santana VM; Hero B; Berthold F; Shulkin BL; Huebner A; Eisenhofer G
Pediatr Blood Cancer; 2020 Feb; 67(2):e28081. PubMed ID: 31724812
[TBL] [Abstract][Full Text] [Related]
13. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
[TBL] [Abstract][Full Text] [Related]
14. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
[TBL] [Abstract][Full Text] [Related]
15. Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression.
Gao J; Jung M; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ
Cancer Res; 2020 Sep; 80(17):3706-3718. PubMed ID: 32651259
[TBL] [Abstract][Full Text] [Related]
16. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
[TBL] [Abstract][Full Text] [Related]
17. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
18. Hormonal activity may predict aggressive behavior in neuroblastoma.
Zambrano E; Reyes-Múgica M
Pediatr Dev Pathol; 2002; 5(2):190-9. PubMed ID: 11910515
[TBL] [Abstract][Full Text] [Related]
19. Plasma free metanephrines for diagnosis of neuroblastoma patients.
Barco S; Verly I; Corrias MV; Sorrentino S; Conte M; Tripodi G; Tytgat G; van Kuilenburg A; van der Ham M; de Sain-van der Velden M; Garaventa A; Cangemi G
Clin Biochem; 2019 Apr; 66():57-62. PubMed ID: 30822416
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets.
Wang H; Wang X; Xu L; Zhang J; Cao H
BMC Pediatr; 2020 Jun; 20(1):314. PubMed ID: 32593299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
